1. Home
  2. CURX vs XAIR Comparison

CURX vs XAIR Comparison

Compare CURX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CURX

Curanex Pharmaceuticals Inc

N/A

Current Price

$0.48

Market Cap

11.6M

Sector

Health Care

ML Signal

N/A

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.72

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CURX
XAIR
Founded
2018
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6M
10.1M
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
CURX
XAIR
Price
$0.48
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
5.4M
137.8K
Earning Date
09-09-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.09
EPS
N/A
N/A
Revenue
N/A
$3,705,000.00
Revenue This Year
N/A
$122.00
Revenue Next Year
N/A
$58.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
219.67
52 Week Low
$0.26
$0.15
52 Week High
$9.18
$3.78

Technical Indicators

Market Signals
Indicator
CURX
XAIR
Relative Strength Index (RSI) 61.12 33.76
Support Level $0.37 $0.67
Resistance Level $0.51 $1.25
Average True Range (ATR) 0.05 0.05
MACD 0.01 0.00
Stochastic Oscillator 63.18 22.53

Price Performance

Historical Comparison
CURX
XAIR

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Share on Social Networks: